Results 41 to 50 of about 382,920 (355)

γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation

Blood Cancer Journal, 2022
We here defined the impacts of γ-secretase inhibitors (GSIs) on T-cell-dependent BCMA-specific multiple myeloma (MM) cell lysis and immunomodulatory effects induced by bispecific antibodies (BisAbs).
Hailin Chen, Tengteng Yu, Liang Lin, Lijie Xing, Shih-Feng Cho, Kenneth Wen, Kimberly Aardalen, Adwait Oka, Joni Lam, Mike Daley, Haihui Lu, Nikhil Munshi, Kenneth C. Anderson, Yu-Tzu Tai   +13 more
doaj   +1 more source

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

The Lancet, 2019
BACKGROUND Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell transplantation is standard treatment in Europe for transplant-eligible patients with newly diagnosed multiple myeloma. We evaluated whether the addition of daratumumab
P. Moreau, M. Attal, C. Hulin, B. Arnulf, K. Belhadj, L. Benboubker, M. Béné, A. Broijl, H. Caillon, D. Caillot, J. Corre, M. Delforge, T. Dejoie, C. Doyen, T. Facon, C. Sonntag, J. Fontan, L. Garderet, K. Jie, L. Karlin, F. Kuhnowski, J. Lambert, X. Leleu, P. Lenain, M. Macro, C. Mathiot, F. Orsini-Piocelle, A. Perrot, A. Stoppa, N. W. van de Donk, S. Wuillème, S. Zweegman, B. Kolb, C. Touzeau, M. Roussel, M. Tiab, J. Marolleau, N. Meuleman, M. Vekemans, M. Westerman, S. Klein, M. Levin, J. Fermand, M. Escoffre-barbe, J. Eveillard, R. Garidi, T. Ahmadi, S. Zhuang, Christopher Chiu, L. Pei, Carla J. de Boer, E. Smith, W. Deraedt, T. Kampfenkel, J. Schecter, J. Vermeulen, H. Avet-Loiseau, P. Sonneveld   +57 more
semanticscholar   +1 more source

Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum

Leukemia Research Reports, 2023
To evaluate the specific prognostic value of CAs, we conducted an analysis of 923 symptomatic multiple myeloma patients. Among this cohort, 480 patients had complete data set of high-risk CAs by interphase fluorescent in situ hybridization at diagnosis ...
Aya Nakaya, Hirohiko Shibayama, Nobuhiko Uoshima, Ryosuke Yamamura, Satoshi Yoshioka, Kazunori Imada, Yuji Shimura, Masaaki Hotta, Toshimitsu Matsui, Satoru Kosugi, Hitoshi Hanamoto, Hitoji Uchiyama, Satoshi Yoshihara, Shin-ichi Fuchida, Yoshiyuki Onda, Yasuhiro Tanaka, Kensuke Ohta, Mitsuhiro Matsuda, Junya Kanda, Adachi Yoko, Miki Kiyota, Eri Kawata, Ryoichi Takahashi, Kentaro Fukushima, Hirokazu Tanaka, Hideo Yagi, Teruhito Takakuwa, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Akifumi Takaori-Kondo, Junya Kuroda, Itaru Matsumura, Masayuki Hino   +33 more
doaj   +1 more source

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.

The Lancet Oncology, 2021
This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma.
P. Moreau, Shaji K. Kumar, J. S. San Miguel, F. Davies, E. Zamagni, N. Bahlis, H. Ludwig, J. Mikhael, E. Terpos, F. Schjesvold, T. Martin, K. Yong, B. Durie, T. Facon, A. Jurczyszyn, S. Sidana, N. Raje, N. V. D. van de Donk, S. Lonial, M. Cavo, S. Kristinsson, S. Lentzsch, R. Hájek, K. Anderson, C. João, H. Einsele, P. Sonneveld, M. Engelhardt, R. Fonseca, A. Vangsted, K. Weisel, R. Baz, V. Hungria, J. Berdeja, F. Leal da Costa, Â. Maiolino, A. Waage, D. Vesole, E. Ocio, H. Quach, C. Driessen, J. Bladé, X. Leleu, E. Riva, P. Bergsagel, J. Hou, W. Chng, U. Mellqvist, D. Dytfeld, J. Harousseau, H. Goldschmidt, J. Laubach, N. Munshi, F. Gay, M. Beksaç, L. Costa, M. Kaiser, P. Hari, M. Boccadoro, S. Usmani, S. Zweegman, S. Holstein, O. Sezer, Simon Harrison, H. Nahi, G. Cook, M. Mateos, S. Rajkumar, M. Dimopoulos, P. Richardson   +69 more
semanticscholar   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Revised International Staging System for Multiple Myeloma: a report from IMWG

Journal of Clinical Oncology, 2015
Purpose The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and reliable tool is needed to stratify MM patients. We combined the International Staging System (ISS) with chromosomal abnormalities (CA) detected by interphase ...
A. Palumbo, H. Avet-Loiseau, S. Oliva, H. Lokhorst, H. Goldschmidt, L. Rosiñol, P. Richardson, S. Caltagirone, J. Lahuerta, T. Facon, S. Bringhen, F. Gay, M. Attal, R. Passera, A. Spencer, M. Offidani, Shaji K. Kumar, P. Musto, S. Lonial, M. Petrucci, R. Orlowski, E. Zamagni, G. Morgan, M A Dimopoulos, B. Durie, K. Anderson, P. Sonneveld, J. Miguel, M. Cavo, S. Rajkumar, P. Moreau   +30 more
semanticscholar   +1 more source

Familial Myeloma [PDF]

New England Journal of Medicine, 2008
We describe a family with five cases of multiple myeloma, three cases of monoclonal gammopathy of undetermined significance (MGUS), and five cases of prostate cancer in two generations. The putative progenitor had progeny with two female partners. The progeny had prostate cancer, multiple myeloma, and MGUS.
Henry T, Lynch, Kelly, Ferrara, Bart, Barlogie, Elizabeth A, Coleman, Jane F, Lynch, Dennis, Weisenburger, Warren, Sanger, Patrice, Watson, Henry, Nipper, Vinetta, Witt, Stephan, Thomé   +10 more
openaire   +2 more sources

Aquaporin‐3 and aquaporin‐5 impact the development of pancreatic ductal adenocarcinoma spheroids

FEBS Open Bio, EarlyView.
Schematic representation of the role of aquaporin‐3 (AQP3) and aquaporin‐5 (AQP5) in pancreatic ductal adenocarcinoma (PDAC). Both proteins are upregulated in PDAC and are associated with tumor progression and metastatic potential. Silencing AQP3 or AQP5 in PDAC spheroids results in decreased diameter, area, and overall growth, underscoring their key ...
Catarina Pimpão, Diogo M. Engrácia, Graça Soveral, Filipa Mendes   +3 more
wiley   +1 more source

From energy provision to protein synthesis: Tunnelling nanotubes as mediators of intercellular metabolic cooperation in cancer

FEBS Open Bio, EarlyView.
The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley   +1 more source